Ketamine and Psychedelic-Assisted Therapy Are Coming for Adolescent Psychiatry
Ketamine and Psychedelic-Assisted Therapy Are Coming for Adolescent Psychiatry. Are We Ready?
The early data is genuinely encouraging. The ethical groundwork is not yet finished. Here's an honest, hopeful look at where this field actually stands for young people today.
Adult psychiatry is in the middle of a genuine paradigm shift. Ketamine clinics have moved from the margins to the mainstream in less than a decade. Psilocybin and MDMA-assisted therapies are working through late-stage trials and, in some places, regulatory approval. For adults with treatment-resistant depression, PTSD, and suicidal crises, these treatments are producing results that traditional antidepressants — built on the same basic mechanism for sixty years — simply haven't matched.
It is only a matter of time before this wave reaches adolescent psychiatry, and in one important sense, it already has. The honest, forward-looking answer to "are we ready" is: partially — the early evidence is real and promising, but the ethical and regulatory scaffolding built for adults hasn't yet been rebuilt for a population whose brains are still developing and whose consent is legally shared with a parent. That gap is closing. It isn't closed yet.
What We Actually Know So Far
The most meaningful adolescent data so far concerns ketamine's chemical cousin, esketamine — already FDA-approved for adults — rather than classic psychedelics like psilocybin or MDMA.
Adult Approval Opens the Door
Esketamine nasal spray receives FDA approval for adults with treatment-resistant depression, and later for adults with major depressive disorder and acute suicidal ideation — establishing the regulatory and clinical infrastructure that adolescent research would eventually build on.
The First Large Adolescent Trial
A phase 2b randomized, placebo-controlled trial enrolls 147 adolescents aged 12 to 17 with major depressive disorder who were at imminent risk for suicide, comparing esketamine nasal spray against an active psychoactive placebo, with everyone also receiving hospitalization, standard antidepressants, and psychotherapy.
A Rapid, Measurable Effect
The combined higher doses of esketamine significantly outperformed placebo in reducing depressive symptoms within 24 hours of the first dose — a striking finding given that traditional antidepressants typically take four to six weeks to show any measurable effect at all, a timeline that can be dangerous in an acute suicidal crisis.
Classic Psychedelics Remain Largely Untested in Minors
A 2025 scoping review of two decades of psychedelic research found that adolescents younger than 18 have been excluded from essentially all modern clinical trials of psilocybin and MDMA-assisted therapy — only a handful of proposed studies exist, and none have been completed or published.
The takeaway is a real distinction worth holding onto: ketamine-based treatment for adolescent depression and suicidality already has meaningful clinical trial data behind it. Classic psychedelic-assisted therapy for adolescents, by contrast, is still almost entirely theoretical — promising by extension from adult data, but not yet studied in this age group in any completed, published way.
This lack of research indicates a critical evidence gap that will impede informed clinical decision-making. — Rajwani et al., scoping review of psychedelic research in adolescents
Why This Field Can't Just Copy the Adult Playbook
Every reason adult psychedelic research moved carefully — informed consent, screening for risk, integration support — applies with even more force to minors, plus several considerations that are unique to adolescence.
Who Is Actually Agreeing to What
A minor can give assent, but legal consent belongs to a parent or guardian — creating a layered decision-making process for a treatment that produces an altered state of consciousness, which is a fundamentally different thing to consent to than a daily pill.
Timing Matters Differently in Adolescence
The adolescent brain is still undergoing active synaptic pruning and prefrontal maturation — a period of unusual neuroplasticity that could make these treatments especially powerful, or could carry risks that simply don't exist in a fully matured adult brain. Right now, we don't fully know which.
The Therapeutic Relationship Carries More Weight
Psychedelic-assisted therapy relies heavily on the guide-patient relationship during an altered state. Adolescents are developmentally more suggestible and more oriented toward pleasing authority figures, raising real questions about influence during vulnerable sessions.
Approval for Adults Doesn't Stay Contained
Once a psychedelic medicine is approved for adults, researchers have noted it will likely be prescribed off-label to adolescents regardless — meaning the field faces a choice between studying this population deliberately now, or having it happen anyway without a solid evidence base.
Many psychiatric medications are already prescribed to adolescents with limited pediatric-specific trial data — this isn't new. Researchers reviewing this field have argued that avoiding adolescent psychedelic research entirely doesn't prevent off-label use; it just means that use happens without the safety data that deliberate research would provide. The genuinely cautious path is careful, ethically constrained research — not indefinite avoidance.
What Responsible Progress Looks Like
None of this argues for slowing down out of fear. It argues for building the right scaffolding as the field moves forward — which is already starting to happen.
- Age-appropriate trial design. The 2024 adolescent esketamine trial is a template: active placebo control, hospitalization as a safety net, concurrent evidence-based psychotherapy, and narrow, well-defined criteria for who qualifies.
- Starting with the highest-need, best-monitored cases. Adolescents at imminent suicide risk — where existing treatments are too slow and the stakes of inaction are highest — represent the most ethically defensible starting point for this research, not broad early access.
- Separating ketamine from classic psychedelics in the conversation. These are chemically and clinically distinct categories with very different evidence bases in this age group. Treating them as one story risks either overselling classic psychedelics or underselling ketamine's real, trial-backed results.
- Building consent frameworks made for altered states. Standard consent forms weren't written with dissociative or psychedelic experiences in mind — adolescent-specific protocols need language and processes that actually fit what the treatment involves.
- Keeping families and long-term follow-up in the picture. Given how new this evidence is, structured long-term monitoring — not just a four-week trial window — will matter enormously for understanding real-world safety in a still-developing brain.
The field is not being reckless, and it's not standing still either. It's threading a genuinely difficult needle: real suffering that current treatments often fail to reach quickly enough, alongside a population that deserves more caution, not less, than the adults these treatments were first tested on.
Cautious Optimism, Held Honestly
The 24-hour response seen in the largest adolescent esketamine trial is worth sitting with. For a teenager in the middle of a suicidal crisis, the difference between relief in a day and relief in six weeks can be the difference that matters most. That's genuinely exciting, and it's a fair reason for hope.
It's also exactly why the ethical work matters as much as the clinical work. Getting this right — for classic psychedelics as much as for ketamine — means building the consent processes, the long-term safety data, and the age-appropriate protocols before this becomes standard practice, not after. Are we ready? Not entirely. But the field is moving toward readiness deliberately, and that, for a population this vulnerable, is exactly how it should happen.
Curious Whether Emerging Treatments Are Right for Your Family?
At Cranbrook Psychiatric Group, we stay current on the evidence behind every treatment we discuss — including where the science is still developing. If your teen is struggling with depression or suicidal thoughts, we can walk you through every option, established and emerging, via telehealth from anywhere in Michigan.
- Rajwani, A. et al. (2025). Clinical Psychedelic Research in Adolescents: A Scoping Review and Overview of Ethical Considerations. The Lancet Child & Adolescent Health.
- Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study (2025). Journal of the American Academy of Child & Adolescent Psychiatry.
- The Renaissance of Research on Psychedelics in Child and Adolescent Psychopharmacology (2026). Child and Adolescent Psychiatry and Mental Health.
- Ethical Issues With Psychedelic-Assisted Treatments in Psychiatry: A Systematic Scoping Review (2025). Psychological Medicine.
- Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution (2024). Journal of the American Academy of Child and Adolescent Psychiatry.
- U.S. Food and Drug Administration. Esketamine (Spravato) Prescribing Information and Approval History.
